JBI-802 for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine differentiation.
Will I have to stop taking my current medications?
The trial requires you to stop using strong inhibitors or inducers of certain enzymes (CYP3A and CYP2D6) at least 14 days before starting the study. If you're on anticoagulants, you must be on a stable dose for at least 2 weeks before joining. Other medications are not specifically mentioned, so it's best to discuss with the trial team.
Who Is on the Research Team?
Program Manager
Principal Investigator
Jubilant Therapeutics Inc.
Are You a Good Fit for This Trial?
Adults with advanced solid tumors that can't be surgically removed or have spread, and who lack effective treatment options. They must have a certain level of organ function and no severe medical conditions or recent use of specific drugs that affect metabolism.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of JBI-802 to determine the maximum-tolerated dose (MTD)
Dose Expansion
Participants receive the recommended Phase 2 dose (RP2D) to evaluate efficacy in specific cancer types
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- JBI-802
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jubilant Therapeutics Inc.
Lead Sponsor